Jaye L. Viner

5.6k total citations · 1 hit paper
47 papers, 3.5k citations indexed

About

Jaye L. Viner is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, Jaye L. Viner has authored 47 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 14 papers in Oncology and 13 papers in Pharmacology. Recurrent topics in Jaye L. Viner's work include Inflammatory mediators and NSAID effects (13 papers), Estrogen and related hormone effects (8 papers) and Colorectal Cancer Treatments and Studies (7 papers). Jaye L. Viner is often cited by papers focused on Inflammatory mediators and NSAID effects (13 papers), Estrogen and related hormone effects (8 papers) and Colorectal Cancer Treatments and Studies (7 papers). Jaye L. Viner collaborates with scholars based in United States, United Kingdom and Australia. Jaye L. Viner's co-authors include Ernest T. Hawk, Lynn M. Matrisian, Louis M. Weiner, Sheila A. Prindiville, Ira Mellman, Andrea Stern Ferris, James P. Allison, Olivera J. Finn, Toby T. Hecht and Martin A. Cheever and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Circulation and Journal of Clinical Oncology.

In The Last Decade

Jaye L. Viner

47 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

2009 1.1k citations Martin A. Cheever, James P. Allison et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jaye L. Viner United States	24	1.5k	1.2k	862	474	356	47	3.5k
Cody J. Peer United States	33	1.8k 1.1×	1.5k 1.3×	626 0.7×	215 0.5×	158 0.4×	156	4.0k
Gilda G. Hillman United States	27	883 0.6×	602 0.5×	535 0.6×	214 0.5×	265 0.7×	79	2.4k
Nicoletta Ferrari Italy	36	2.0k 1.3×	785 0.7×	611 0.7×	217 0.5×	243 0.7×	113	3.7k
Quansheng Zhou China	37	2.3k 1.5×	640 0.5×	871 1.0×	282 0.6×	162 0.5×	89	3.7k
Mitsuo Katano Japan	44	2.9k 1.9×	2.1k 1.7×	1.3k 1.5×	323 0.7×	322 0.9×	157	5.5k
Ramzi M. Mohammad United States	41	2.9k 1.9×	1.2k 1.0×	374 0.4×	262 0.6×	154 0.4×	154	4.8k
Amy M. Fulton United States	40	1.2k 0.8×	1.8k 1.5×	1.8k 2.0×	1.2k 2.6×	767 2.2×	95	4.7k
Venkateshwar G. Keshamouni United States	31	2.0k 1.3×	800 0.7×	627 0.7×	209 0.4×	204 0.6×	49	3.5k
Zhangang Xiao China	38	2.0k 1.3×	935 0.8×	829 1.0×	151 0.3×	182 0.5×	137	4.1k
Jaydutt V. Vadgama United States	41	2.4k 1.6×	1.6k 1.3×	400 0.5×	162 0.3×	455 1.3×	130	4.5k

Countries citing papers authored by Jaye L. Viner

Since Specialization

Citations

This map shows the geographic impact of Jaye L. Viner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaye L. Viner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaye L. Viner more than expected).

Fields of papers citing papers by Jaye L. Viner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jaye L. Viner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaye L. Viner. The network helps show where Jaye L. Viner may publish in the future.

Co-authorship network of co-authors of Jaye L. Viner

This figure shows the co-authorship network connecting the top 25 collaborators of Jaye L. Viner. A scholar is included among the top collaborators of Jaye L. Viner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jaye L. Viner. Jaye L. Viner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sun, Kaiming, Ruzanna Atoyan, Mylissa Borek, et al.. (2016). Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers. Molecular Cancer Therapeutics. 16(2). 285–299. 109 indexed citations

Younes, Anas, Jesús G. Berdeja, Manish R. Patel, et al.. (2016). Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. The Lancet Oncology. 17(5). 622–631. 156 indexed citations

Linden, Kenneth G., Sancy A. Leachman, Jonathan S. Zager, et al.. (2014). A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology. Cancer Prevention Research. 7(5). 496–504. 20 indexed citations

Haluska, Paul, Michael E. Menefee, Elizabeth R. Plimack, et al.. (2014). Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 20(18). 4747–4757. 55 indexed citations

Sabichi, Anita L., J. Jack Lee, H. Barton Grossman, et al.. (2011). A Randomized Controlled Trial of Celecoxib to Prevent Recurrence of Nonmuscle-Invasive Bladder Cancer. Cancer Prevention Research. 4(10). 1580–1589. 42 indexed citations

Cheever, Martin A., James P. Allison, Andrea Stern Ferris, et al.. (2009). The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research. Clinical Cancer Research. 15(17). 5323–5337. 1050 indexed citations breakdown →

Mutch, Matthew G., Robert E. Schoen, James W. Fleshman, et al.. (2009). A Multicenter Study of Prevalence and Risk Factors for Aberrant Crypt Foci. Clinical Gastroenterology and Hepatology. 7(5). 568–574. 33 indexed citations

Hawk, Ernest T. & Jaye L. Viner. (2006). What Is the Future of Oncology? National Cancer Institute Initiatives to Improve Research, Development, and Implementation in Cancer Prevention and Treatment. Seminars in Oncology. 33(6 Suppl 11). 6–9. 3 indexed citations

Hawk, Ernest T., Asad Umar, & Jaye L. Viner. (2004). Colorectal cancer chemoprevention—an overview of the science1 1This article was prepared in our capacity as employees of the U.S. Federal Government.. Gastroenterology. 126(5). 1423–1447. 60 indexed citations

10.

Linden, Kenneth G., Philip M. Carpenter, Christine E. McLaren, et al.. (2003). Chemoprevention of Nonmelanoma Skin Cancer: Experience with a Polyphenol from Green Tea. Recent results in cancer research. 163. 165–171. 26 indexed citations

11.

Steele, Vernon E., Ernest T. Hawk, Jaye L. Viner, & Ronald A. Lubet. (2003). Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutation research. Fundamental and molecular mechanisms of mutagenesis. 523-524. 137–144. 78 indexed citations

12.

Hawk, Ernest T., Jaye L. Viner, Ellen Richmond, & Asad Umar. (2003). Non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention. PubMed. 21. 759–789. 4 indexed citations

13.

Umar, Asad, Jaye L. Viner, Ellen Richmond, William F. Anderson, & Ernest T. Hawk. (2002). Chemoprevention of colorectal carcinogenesis. International Journal of Clinical Oncology. 7(1). 2–26. 15 indexed citations

14.

Hawk, Ernest T., Paul J. Limburg, & Jaye L. Viner. (2002). Epidemiology and prevention of colorectal cancer. Surgical Clinics of North America. 82(5). 905–941. 87 indexed citations

15.

Umar, Asad, Jaye L. Viner, & Ernest T. Hawk. (2001). The Future of Colon Cancer Prevention. Annals of the New York Academy of Sciences. 952(1). 88–108. 30 indexed citations

16.

Kelloff, Gary J., James A. Crowell, Vernon E. Steele, et al.. (2000). Progress in Cancer Chemoprevention: Development of Diet-Derived Chemopreventive Agents. Journal of Nutrition. 130(2). 467S–471S. 382 indexed citations

17.

Hawk, Ernest T., Jaye L. Viner, & Julia Lawrence. (2000). Biomarkers as surrogates for cancer development. Current Oncology Reports. 2(3). 242–250. 13 indexed citations

18.

Hassan, Raffit, Jaye L. Viner, Qingcheng Wang, et al.. (2000). Anti-Tumor Activity of K1-LysPE38QQR, an Immunotoxin Targeting Mesothelin, a Cell-Surface Antigen Overexpressed in Ovarian Cancer and Malignant Mesothelioma. Journal of Immunotherapy. 23(4). 473–479. 57 indexed citations

19.

Viner, Jaye L., et al.. (1999). Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2.. PubMed. 59(16). 4018–22. 33 indexed citations

20.

Kelloff, Gary J., James A. Crowell, Vernon E. Steele, et al.. (1999). Progress in Cancer Chemoprevention. Annals of the New York Academy of Sciences. 889(1). 1–13. 114 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact